NCT04007263View on ClinicalTrials.gov

A Multiple Ascending Dose Study of Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 4, 2019

Primary Completion Date

August 30, 2019

Study Completion Date

October 10, 2019

Conditions
Stroke, IschemicPain, PostoperativeSubstance AbuseSubarachnoid Hemorrhage
Interventions
DRUG

Placebo

Placebo via 30 minute infusion once daily for 5 days

DRUG

NP10679

NP10679 25 mg via 30 minute infusion once daily for 5 days

Trial Locations (1)

21201

Pharmaron CPC, Baltimore

Sponsors

Lead Sponsor

Neurop Inc.

Collaborators (1)

Pharmaron
All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

collaborator

Pharmaron

INDUSTRY

lead

Neurop Inc.

INDUSTRY

NCT04007263 - A Multiple Ascending Dose Study of Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers | Biotech Hunter | Biotech Hunter